Do Allergy Shots Actually Work? When They Succeed and When They Fail
Allergy shots actually work for 50-80% of patients based on clinical trial evidence — but the word 'actually' matters, because 20-50% get suboptimal results. The gap between success and failure usually comes down to identifiable, often preventable factors: wrong allergen identified, insufficient dose, premature discontinuation, or non-IgE conditions. Understanding these failure modes turns an abstract yes-or-no question into an actionable checklist for maximizing your own chances of success.
6 peer-reviewed sources
Yes, allergy shots actually work — 50-80% of patients achieve meaningful improvement in controlled trials. The 20-50% who don't respond well almost always have an identifiable reason: wrong allergen targeted, inadequate dose, stopping too soon, or a non-allergic rhinitis component.
Success vs Failure: What Actually Determines Whether Shots Work for You
The 'actually' in this question carries a specific meaning: the searcher has heard allergy shots work in theory but wants to know whether they work in practice, and whether they'll work for them specifically. The honest answer addresses both.
In controlled clinical trials, allergy shots significantly outperform placebo — the Cochrane meta-analysis of 51 trials (Calderon et al., 2007) found a pooled symptom SMD of -0.73, with 50-80% of patients achieving clinically meaningful improvement. That's not a theoretical number from a lab; it's from patients receiving actual injections in actual clinics.
But 50-80% means 20-50% don't achieve full improvement. Unlike a drug that works chemically regardless of who takes it, allergy shots work by targeting specific immune responses to specific allergens — making the accuracy of your initial diagnosis, the adequacy of your dose, and your adherence to the full protocol major determinants of your individual outcome.
The good news: most of the reasons allergy shots fail are identifiable before or during treatment. Wrong allergen identification — up to 30% of patients have discordant skin prick test and specific IgE results — is the top preventable failure mode. At-home allergy testing from Curex provides specific IgE blood panels covering 40+ allergens, helping ensure that any immunotherapy targets the right triggers from the start.
This page walks through the success conditions and the failure modes in detail — not to discourage you, but to give you the information needed to be an informed participant in your own treatment.
Allergy shots work for most patients who receive the right treatment for the right allergens at adequate doses for a full course — the 20-50% who don't respond well almost always have an identifiable, often addressable reason.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
When Allergy Shots Succeed vs When They Fail: The Full Analysis
Understanding the variables that determine allergy shot outcomes converts an abstract question into a practical checklist. Four major modifiable factors determine whether a given patient's allergy shots 'actually work.' Success factor 1 — Correct allergen identification: Allergy shots only work when they target allergens that are genuinely driving your immune response. Skin prick testing and specific IgE blood testing identify sensitizations, but sensitization doesn't always equal clinical allergy. Up to 30% of patients have discordant results between SPT and sIgE testing (Cox et al., JACI, 2011). When the wrong allergen is treated, the immune retraining has no relevant target — and improvement is limited regardless of how faithfully the patient follows the protocol. Success factor 2 — Adequate maintenance dose: Each major allergen has a documented therapeutic dose range — roughly 5-20 micrograms of the major allergen per injection (Cox et al., JACI, 2011). Patients who plateau below this threshold due to local reactions or conservative dose escalation have reduced efficacy. This is a modifiable clinical variable your allergist can adjust. Success factor 3 — Completing 3+ years: Patients completing 3 or more years of maintenance have significantly better long-term outcomes than those who discontinue early (Durham et al., NEJM, 1999). Real-world completion rates are sobering — Kiel et al. (2013) found only 23% of SCIT patients completed 3 years in a large Dutch pharmacy database. Premature discontinuation is the single most common reason allergy shots 'don't work' when the mechanism was actually working. Success factor 4 — Correct condition: SCIT works for IgE-mediated allergic disease. Patients with non-allergic rhinitis, vasomotor rhinitis, or a significant non-allergic rhinitis component (mixed rhinitis, which affects 34-74% of rhinitis patients) may see incomplete benefit even when shots are correctly targeted and dosed.
Success Rate by Duration
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youMaximizing Your Chances: SCIT Success Checklist vs Alternatives
For patients trying to decide whether allergy shots will 'actually work' for them, comparing SCIT to alternatives — including SLIT — is a useful frame. The success factors for SCIT (correct allergen ID, adequate dose, adherence) also apply to SLIT. The biggest adherence barrier has been the 57-60 clinic visits a traditional shot course requires — the most common reason SCIT patients stop early — but at-home SCIT through Curex removes those trips while keeping the shot route: eligible patients self-inject at home, with the first dose and every dose change supervised live over Zoom.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (SCIT) — CurexBest | 50-80% success with correct allergen targeting, adequate dose, and 3-year completion | 3-5 years of clinic injections | $3,000-$15,000 | Self-administered at home with Curex; first dose and dose changes supervised live over Zoom — removes the 57-60 clinic visits that are a major adherence barrier | ~0.1% systemic reaction per injection; at home with Curex, a USP <797> sterile-compounded serum, a prescribed epinephrine auto-injector confirmed on hand, and Zoom-supervised first and dose-change injections keep it safe for eligible patients |
Sublingual Drops (SLIT) | Comparable efficacy for most allergens; same success factors apply; better adherence rates | 3-5 years of daily at-home drops | $1,400-$5,000 | At-home daily drops; eliminates the clinic-visit barrier that causes most early discontinuation | Zero documented fatalities; local oral reactions; no systemic anaphylaxis deaths on record |
Daily Antihistamines | Works reliably while taken; no failure modes from wrong allergen targeting | Indefinite daily use | $600-$2,000 | Simple daily pill | Safe; sedation with older agents |
- Efficacy
- 50-80% success with correct allergen targeting, adequate dose, and 3-year completion
- Duration
- 3-5 years of clinic injections
- Cost (5yr)
- $3,000-$15,000
- Convenience
- Self-administered at home with Curex; first dose and dose changes supervised live over Zoom — removes the 57-60 clinic visits that are a major adherence barrier
- Safety
- ~0.1% systemic reaction per injection; at home with Curex, a USP <797> sterile-compounded serum, a prescribed epinephrine auto-injector confirmed on hand, and Zoom-supervised first and dose-change injections keep it safe for eligible patients
- Efficacy
- Comparable efficacy for most allergens; same success factors apply; better adherence rates
- Duration
- 3-5 years of daily at-home drops
- Cost (5yr)
- $1,400-$5,000
- Convenience
- At-home daily drops; eliminates the clinic-visit barrier that causes most early discontinuation
- Safety
- Zero documented fatalities; local oral reactions; no systemic anaphylaxis deaths on record
- Efficacy
- Works reliably while taken; no failure modes from wrong allergen targeting
- Duration
- Indefinite daily use
- Cost (5yr)
- $600-$2,000
- Convenience
- Simple daily pill
- Safety
- Safe; sedation with older agents
The top preventable reason allergy shots fail is wrong allergen identification — specific IgE blood testing confirms exact triggers and reduces this most common failure mode. For patients who want to maximize success probability with a treatment they can actually complete, Curex delivers the shot route itself as an at-home allergy shot kit (SCIT) for $129/month all-inclusive — a personalized serum sterile-compounded to USP <797>, one weekly shot you give yourself at home, and your first dose and every dose change supervised live over Zoom by a board-certified allergist after a prescribed epinephrine auto-injector is confirmed on hand — removing the clinic-visit burden that drives the 30-50% premature discontinuation rate.
See if at-home shots are right for youFrequently asked questions
What are the most common reasons allergy shots don't work?
The most common reasons allergy shots don't produce the expected benefit fall into four categories. First, wrong allergen identification — up to 30% of patients have discordant results between skin prick and specific IgE blood testing, meaning treatment may target sensitizations rather than true clinical drivers. Second, insufficient maintenance dose — patients who don't reach the therapeutic target of 5-20 micrograms of major allergen due to local reactions or conservative dosing have reduced efficacy. Third, premature discontinuation — patients stopping before 3 years of maintenance have significantly higher relapse rates; real-world data show only 23% of SCIT patients complete 3 years. Fourth, non-IgE conditions — patients with mixed rhinitis (allergic plus vasomotor components) may have their IgE-driven symptoms improve while non-allergic symptoms persist, leading to the perception that shots 'aren't working.'
How long should I give allergy shots before deciding they're not working?
The AAAAI/ACAAI Practice Parameter specifies that a minimum of one full year of adequate maintenance dosing is required before concluding allergy shots are ineffective — not one year from the first injection, but one year from reaching the maintenance dose. This means build-up time (3-6 months) plus 12 months of maintenance: a total of 15-18 months minimum before a fair assessment. Declaring failure earlier than this is almost always premature; the immune tolerance changes are still actively accumulating during this window. If after a full year of verified adequate maintenance dosing there is still no clinically meaningful improvement, your allergist should reassess allergen selection, dosing adequacy, and whether a non-IgE component may be contributing — before recommending discontinuation.
Who is most likely to benefit from allergy shots?
Research identifies several predictors of better allergy shot outcomes. Monosensitization — being allergic to one or two allergens rather than many — is associated with better long-term benefit, particularly durability after stopping treatment (Yuan et al., Otolaryngol Head Neck Surg, 2024). Younger age at treatment start and shorter disease duration correlate with more robust responses, suggesting that treating allergic disease earlier in its natural history produces better outcomes. High baseline specific IgE levels (for example, HDM-specific IgE above 17.5 kU/L) were associated with higher remission rates in a Korean cohort study (Lee et al., 2018). More severe baseline symptoms paradoxically predict somewhat lower remission rates in some studies, though this may reflect harder-to-treat disease rather than inherent treatment failure. A board-certified allergist can evaluate these factors to give you an individualized probability of benefit.
Can allergy shots fail even if you do everything right?
Yes — even under optimal conditions (correct allergens, adequate doses, full 3-5 year course, no contraindications), some patients simply don't respond. The clinical data shows 20-50% of patients get partial or insufficient benefit even in well-designed trials with carefully selected patients and verified dosing. The mechanism of non-response in these cases is not fully understood; factors like genetic variation in immune response genes, heterogeneity in the precise molecular allergen components driving disease, and differences in mucosal immune architecture likely contribute. For patients who don't respond to SCIT, alternative approaches include re-evaluation of allergen selection using component-resolved diagnostics, assessment for non-allergic rhinitis components, consideration of biologic medications for coexisting conditions, or discussion of whether SLIT might be a viable alternative route.
What happens if allergy shots stop working after years of improvement?
Some patients experience a gradual return of symptoms after years of good control — either while still on maintenance or years after stopping. This can happen for several reasons: development of new sensitizations to allergens not included in the original treatment mix; environmental changes that increase your overall allergen load; waning of the immune tolerance established during treatment (more common in patients who stopped after only 2-3 years); or comorbid conditions like chronic sinusitis masking continued immunotherapy benefit. If symptoms return while still on maintenance, discuss dose adequacy, extract freshness (extracts degrade over time), and whether new sensitizations should be added to treatment. If symptoms return years after stopping a completed course, a second course of immunotherapy is appropriate and typically works faster than the original treatment.
Do predictors exist for identifying who won't respond to allergy shots?
Research has identified several predictors of poorer response, though none are absolute contraindications for appropriate candidates. Severe baseline rhinitis was associated with lower remission odds in the Lee et al. (2018) cohort study (OR 0.40 for severe versus mild baseline disease). Polysensitization — particularly to 5 or more allergens — is associated with more complex treatment planning and potentially less complete benefit from the single-allergen-focused approach; Yuan et al. (2024) found monosensitized children maintained significantly better benefit at 2 years post-treatment than polysensitized peers. Non-IgE-mediated disease, confirmed by negative specific IgE testing despite positive skin prick tests, predicts poor response. Patients with coexisting uncontrolled asthma are also contraindicated from SCIT until asthma is stabilized. A board-certified allergist can identify these predictors before treatment begins.
Related Articles
How Long Do Allergy Shots Take? Trial vs Reality | Curex
How long do allergy shots take to work? Trials show 12-month benefit, but only 23% complete 3 years. Real-world vs clinical data guide.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT trains your immune system to tolerate allergens over 3-5 years. 85-90% of patients see significant improvement.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreAllergy Shots: Complete SCIT Guide for Patients | Curex
Allergy shots (SCIT) reduce symptoms by 33-85% over 3-5 years. Learn how they work, what they cost, and who qualifies for this disease-modifying treatment.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.